285 related articles for article (PubMed ID: 25485927)
1. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A
Redox Biol; 2015; 4():23-33. PubMed ID: 25485927
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
Salem K; Brown CO; Schibler J; Goel A
Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
4. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
Tibullo D; Giallongo C; Romano A; Vicario N; Barbato A; Puglisi F; Parenti R; Amorini AM; Wissam Saab M; Tavazzi B; Mangione R; Brundo MV; Lazzarino G; Palumbo GA; Volti GL; Raimondo FD; Lazzarino G
Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365811
[TBL] [Abstract][Full Text] [Related]
6. The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib.
Łuczkowska K; Kulig P; Baumert B; Machaliński B
Nutrients; 2022 Dec; 14(23):. PubMed ID: 36501221
[TBL] [Abstract][Full Text] [Related]
7. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
8. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
9. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
[TBL] [Abstract][Full Text] [Related]
10. 5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
Łuczkowska K; Kulig P; Rusińska K; Baumert B; Machaliński B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069103
[TBL] [Abstract][Full Text] [Related]
11. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
[TBL] [Abstract][Full Text] [Related]
12. Altered redox regulation and S-glutathionylation of BiP contribute to bortezomib resistance in multiple myeloma.
Zhang J; Ye ZW; Chen W; Culpepper J; Jiang H; Ball LE; Mehrotra S; Blumental-Perry A; Tew KD; Townsend DM
Free Radic Biol Med; 2020 Nov; 160():755-767. PubMed ID: 32937189
[TBL] [Abstract][Full Text] [Related]
13. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
14. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
15. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
16. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
17. The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma.
Nikesitch N; Rebeiro P; Ho LL; Pothula S; Wang XM; Khong T; Quek H; Spencer A; Lee CS; Roberts TL; Ling SCW
Cells; 2021 Dec; 10(12):. PubMed ID: 34943972
[No Abstract] [Full Text] [Related]
18. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
[TBL] [Abstract][Full Text] [Related]
19. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
Xu X; Liu J; Huang B; Chen M; Yuan S; Li X; Li J
Tumori; 2017 May; 103(3):261-267. PubMed ID: 27647225
[TBL] [Abstract][Full Text] [Related]
20. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
